CGEM
CGEM
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
3
$13.32M
Insider Sales
35
$3.11M
Total Volume
$16.43M
63 transactions
Net Activity
+$10.21M
Net buying
Sentiment Rating
Moderate AccumulationCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Strong buying bias: purchases represent 81% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
S - Sale+OE Insiders
$29442.36B total
Lynx1 Capital Management LP
10%
$13.32M total
Michaelson Jennifer
Chief Scientific Officer
$1.84M total
Ahmed Nadim
Pres, CEO
$725K total
Jones Jeffrey Alan
Chief Medical Officer
$274K total
Quick Actions
CGEM has an insider buy conviction of 81%, compared to the Unknown sector buy average of 6%. CGEM ranks #495 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at CGEM (CGEM) engaged in a total of 63 transactions reported via SEC Form 4 filings. Among these, 3 were open-market purchases and 35 were sales. The total volume of insider trading reached $16.43M.
The net insider activity for CGEM shows a net buying bias of $10.21M. This activity represents a 81% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 16.19M shares valued at $23638.63B on Oct 8, 2025.
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history
How Cullinan Oncology Inc. (CGEM) Affects Rotational Strategy Timing
Cullinan Therapeutics (Nasdaq:CGEM) - Stock Analysis
Cullinan Oncology LLC (CGEM) Stock Price, Chart & Analysis
$CGEM stock is down 21% today. Here's what we see in our data.
CGEM - Cullinan Therapeutics Inc Stock Price and Quote
FAQs About CGEM Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for CGEM.